Methods of enriching and using regulatory t cells
AssigneeThe United States of America, as represented by the Secretary, Department of Health and
InventorsDat Tran, Ethan M. Shevach
Life of this patent
Estimating the term…
Abstract
Disclosed are methods of isolating and using a population of FOXP3+ regulatory T cells in a variety of preventative and therapeutic approaches to autoimmune diseases, graft-versus-host disease and transplant rejection.
Claims33
A method of making an isolated population of FOXP3+ regulatory T cells, comprising
- obtaining a biological sample containing T-cells from a mammal;
- and,
- contacting the biological sample with a labeled antibody or antibody fragment that specifically recognizes a cell surface protein selected from the group consisting of latency-associated peptide (LAP), IL-1 receptor type I (CD121a), IL-1 receptor type II (CD121b) and GARP (LRRC32) to identify and isolate FOXP3+ T cells from T cells in the biological sample that are FOXP3−.
(canceled)
6-8. (canceled)
(canceled)
(canceled)
15-17. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
31-37. (canceled)
(canceled)
A method of analyzing a biological sample from a mammal for the presence of FOXP3+ regulatory T cells, comprising:
- contacting the biological sample with a labeled antibody that specifically recognizes a cell surface protein selected from the group consisting of latency-associated peptide (LAP), IL-1 receptor type I (CD121a), IL-1 receptor type II (CD121b) and GARP (LRRC32);
- and,
- quantitating the presence of FOXP3+ T regulatory cells in the sample, wherein the presence of the cell surface protein as compared to a control sample lacking FOXP3+ cells is indicative of the presence of regulatory T cells in the test sample.
41-66. (canceled)
A method of treating or preventing a disorder selected from the group consisting of an autoimmune disorder, graft-versus-host disease, and transplant rejection in a mammal comprising administering a population of isolated FOXP3+ T-cells to a mammal selected from the group consisting of a mammal suffering an autoimmune disorder or graft-versus-host disease, a donor of a transplant tissue, and a recipient of a transplant tissue.
69-74. (canceled)
Dependencies are inferred from the claim text.